Welcome to our dedicated page for Guardant Health news (Ticker: GH), a resource for investors and traders seeking the latest updates and insights on Guardant Health stock.
Guardant Health, Inc. (Nasdaq: GH) is a precision oncology company that regularly issues news about its blood and tissue tests, real-world data initiatives, and AI analytics in cancer care. This news page aggregates company announcements, press releases, and other updates so readers can follow how Guardant’s technologies are being used in screening, monitoring, and treatment selection for cancer.
Recent Guardant Health news has covered topics such as preliminary financial results and test volumes, payer coverage milestones for the Shield blood test for colorectal cancer screening, and collaborations aimed at expanding access to oncology clinical trials. The company also reports on scientific presentations that highlight the performance of Guardant Reveal for minimal residual disease detection and therapy response monitoring, and Guardant360 Liquid for multiomic profiling and breast cancer subtyping.
Guardant’s updates frequently describe how its tests are applied across all stages of care, including early detection, recurrence monitoring, and advanced cancer management. News items also include information about partnerships with hospitals and research centers, participation in healthcare and investor conferences, and initiatives related to data infrastructure and AI-ready environments for large-scale genomic datasets.
Investors, clinicians, researchers, and others interested in Guardant Health can use this page to review the company’s latest press releases and historical announcements. By browsing this feed, readers can see how Guardant’s portfolio of liquid biopsy and precision oncology diagnostics is being deployed in clinical practice, research collaborations, and broader efforts to improve access to cancer screening and personalized treatment.
Guardant Health (Nasdaq: GH) announced a collaboration with Boehringer Ingelheim to develop the Guardant360® CDx liquid biopsy as a companion diagnostic for zongertinib, an investigational treatment for non-small cell lung cancer (NSCLC). The blood test will identify NSCLC patients with HER2 mutations who may benefit from zongertinib treatment.
According to Guardant Health's chairman, approximately 40,000 people worldwide are diagnosed annually with NSCLC with HER2 mutations, who often respond poorly to standard treatments. The Guardant360 CDx is already FDA-approved for comprehensive liquid biopsy in advanced solid tumors and serves as a companion diagnostic for multiple NSCLC targeted therapies and breast cancer therapy targeting ESR1 mutations.
Guardant Health (Nasdaq: GH) announced upcoming presentations at the San Antonio Breast Cancer Symposium (SABCS) 2024, showcasing research on their liquid biopsy tests and AI analytics. The company will present eight posters, including a spotlight presentation on the Guardant Reveal test, which investigates circulating tumor DNA (ctDNA) dynamics in breast cancer treatment.
The research suggests that ctDNA analysis could help predict endocrine therapy sensitivity and long-term outcomes in HR+ breast cancer. The presentations will cover various topics including molecular profiling, minimal residual disease testing, and real-world data analysis using Guardant's products such as GuardantINFORM, Guardant Infinity, Guardant360 CDx, and Guardant Reveal.
A federal court jury unanimously ruled in favor of Guardant Health in its lawsuit against Natera for false advertising and unfair competition. The jury awarded $292.5 million to Guardant Health, including $175.5 million in punitive damages, making it one of the largest false advertising verdicts in history. The case, filed in May 2021, centered on Natera's deliberate campaign to mislead cancer clinicians about Guardant Reveal™, a tissue-free minimal residual disease test for early-stage colorectal cancer. The jury rejected all of Natera's counterclaims.
Guardant Health (Nasdaq: GH) announced the approval of equity grants to new non-executive employees under its 2023 Employment Inducement Incentive Award Plan. The grants include 233,603 restricted stock units (RSUs) to 123 employees and stock options to purchase 50,349 shares to three employees. The RSUs vest annually over three years, while the stock options, priced at $28.16 per share, vest one-third after one year and monthly thereafter over 24 months. These grants were made in accordance with Nasdaq Listing Rule 5635(c)(4) as employment inducements.
Guardant Health (GH) reported strong Q3 2024 financial results with revenue of $191.5 million, marking a 34% increase year-over-year. The company performed 53,100 clinical tests and 10,500 biopharma tests, up 21% and 40% respectively. Key highlights include achieving a Guardant360 ASP over $3,000 and receiving favorable Medicare pricing of $920 for Shield. The company raised its 2024 revenue guidance to $720-725 million, representing 28-29% growth. Free cash flow improved to $(55) million from $(80) million in the prior year. Despite revenue growth, the company reported a net loss of $107.8 million for Q3 2024.
Guardant Health (Nasdaq: GH) has announced its participation in four major healthcare investor conferences in November and December. The company will attend the Guggenheim Inaugural Healthcare Innovation Conference in Boston (Nov 12), the Wolfe Healthcare Conference in New York (Nov 19), the Jefferies London Healthcare Conference (Nov 20), and the Piper Sandler Healthcare Conference in New York (Dec 3). The events will feature fireside chats, presentations, and one-on-one meetings. Live and archived webcasts will be available on the company's website investor section.
Guardant Health's blood-based colorectal cancer screening product Shield has been named to TIME's Best Inventions of 2024 list. Shield, which is the first FDA-approved and Medicare-reimbursed colorectal cancer screening blood test, was recognized among 200 extraordinary innovations. The company recently achieved significant milestones, including 500 peer-reviewed publications and over 500,000 patient tests delivered. Shield received FDA approval in July 2024 and subsequent Medicare reimbursement, marking a significant advancement in early cancer detection technology.
Guardant Health (GH) announced upcoming presentations at the American College of Gastroenterology (ACG) 2024 Annual Meeting highlighting the importance of blood-based colorectal cancer (CRC) screening. A key study of over 350,000 patients revealed that less than 50% of patients completed recommended repeat stool-based CRC screening over a four-year period. The company will also present data from the ECLIPSE study examining one-year outcomes of individuals tested with their Shield™ blood test, showing no difference in non-colorectal malignancy rates between positive and negative test results.
Guardant Health (Nasdaq: GH) announced the appointment of Roberto A. Mignone to its board of directors. Mignone, the Founder and Managing Partner of Bridger Management , brings healthcare industry expertise and business strategy experience to the company. He currently serves as co-Vice Chairman at NYU Langone Medical Center and board member at Teva Pharmaceuticals. The appointment follows Guardant Health's FDA approval of Shield, its early-stage colorectal cancer screening product.
Guardant Health (Nasdaq: GH), a leading precision oncology company, has announced it will report its third quarter 2024 financial results after market close on Wednesday, November 6, 2024. The company management will host a conference call and webcast at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on the same day to discuss the results.
Interested parties can access the live audio webcast on the 'Investors' section of the Guardant Health website at www.guardanthealth.com. For those unable to attend the live event, an archived version of the webcast will be available for replay after the call.